Anti-MAG (Myelin Associated Glycoprotein) Neuropathy

Pinpointing diagnosis with precision testing

Myelin associated glycoprotein (MAG) antibody presence is often linked to a distal demyelinating neuropathy with poor treatment response. In some cases, however, reaching correct diagnosis through clinical and electrophysiological evaluation alone can be difficult due to overlapping features, or when patient evaluation occurs later in the disease course. Incorporating MAG antibody testing into the diagnostic workup can help identify the correct diagnosis and exclude patients with treatable immune-mediated neuropathies.

Diagnose with confidence

Utilizing a semi-quantitative ELISA platform and human MAG antigen with improved specificity, the assay equips physicians with more accurate information about the presence of MAG antibodies.

When to consider testing

Consider MAG autoantibody testing in the following instances:

  • Inconclusive electrodiagnostic studies
  • IgM Monoclonal protein (M-Protein) and neuropathy presence
  • Suspicion of Distal Acquired Demyelinating Sensory (DADS) neuropathy

Which test should I order?

A Test in Focus

John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat condition known as DADS neuropathy. 

The role of MASS-FIX

Although most anti-MAG neuropathy cases have an associated IgM M-protein, in some cases testing using traditional approaches (such as serum electrophoresis and immunofixation) can be negative, which delays IgM M-protein discovery. MASS-FIX is a pioneering mass spectrometry assay that enables enhanced sensitivity and specificity compared to traditional approaches when looking for the presence of M-Proteins in the blood.

Interested in learning more? Click here.

Learn more about how to order this evaluation at your institution.